Royalty Report: Drugs, Therapeutic, Disease – Collection: 1296

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 11

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Antibody
  • Immune
  • Cancer
  • Delivery
  • Device
  • Vaccine
  • Gastrointestinal

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1296

License Grant
The Company licensed rights to the use of MTCH-24(tm) against three viruses, the aids virus (hiv), Epstein-Barr virus and cytomegalovirus to a party for an ownership share.
License Property
MTCH-24 is an anti-microbial agent effective against a wide range of other enveloped viruses such as influenza, Epstein-Barr virus (EBV), respiratory syncytial virus (RSV, a virus which affects the respiratory system), pseudorabies (a specific virus in the rabies family), rhino tracheitis (an infection of the lungs and throat), and cytomegalovirus (CMV).  It is also believed to be effective against rotavirus, a non-enveloped virus that is a major cause of diarrhea and inflammation of the intestinal tract in infants and in certain animals.  MTCH-24 (TM) has been shown to be effective in inhibiting and preventing the growth of Aspergillus on wheat and corn.

IPSCIO Record ID: 390

License Grant
The Licensee of Vancouver, Canada, was granted the exclusive license for MTCH-24 and Viraplex® products worldwide outside of the United States.   We have developed two patented compounds: MTCH-24(TM) and Viraplex(R). Both of these compounds show positive test results for treatment of a variety of enveloped viruses.
License Property
MTCH-24(TM) – Herpes I and II are enveloped viruses.  How MTCH-24 acts against enveloped viruses is not fully understood.  However, based on laboratory tests conducted for our company, MTCH-24 is believed to be effective against a wide range of other enveloped viruses such as influenza, Epstein-Barr virus (EBV), respiratory syncytial virus (RSV, a virus which affects the respiratory system), pseudo rabies (a specific virus in the rabies family), rhino tracheitis (an infection of the lungs and throat), and cytomegalovirus (CMV).   It is also believed to be effective against rotavirus, a non-enveloped virus that is a major cause of diarrhea and inflammation of the intestinal tract in infants and in certain animals.

Viraplex(R), which is intended to be administered orally in capsule form as a prescription treatment for oro-facial and genital Herpes simplex virus infections, is in an advanced phase (the third of three phases) of clinical testing for safety and effectiveness in humans although such clinical testing has been suspended pending refinancing of the Company.
Viraplex(R) gave positive in vitro results against several forms of cancer, including breast, prostate and lung tumors.

The Company has developed over-the-counter products containing MTCH-24(tm) for treating the symptoms of herpes simplex virus infections of the lips, mouth or face known as cold sores and for the treatment of acne collectively, the 'OTC products'.

IPSCIO Record ID: 239031

License Grant
The original agreement is to co-promote the Product in the Territory.  This amendment to the Agreement is to extend the special consideration for Synagis sales.
License Property
Synagis is an antibody that provides the immune system with an increased ability to prevent infection.
Field of Use
The use is for respiratory syncytial virus ('RSV'), the leading cause of lower respiratory tract infections and pneumonia in infants and children worldwide.

IPSCIO Record ID: 1165

License Grant
The license agreement assigns to the Licensee, Viratek’s exclusive license from a University covering the aerosol device used to deliver ribavirin (Virazole(R)) to the lungs.
License Property
VIRAZOLE® is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to Respiratory Syncytial Virus (RSV). Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy.
Field of Use
Ribavirin is an anti-viral drug indicated for severe RSV infection (individually), hepatitis C infection (used in conjunction with peginterferon alfa-2b or peginterferon alfa-2a), and other viral infections.

IPSCIO Record ID: 239030

License Grant
The original agreement is to co-promote the Product in the Territory.  This amendment to the Agreement is to provide special consideration for Synagis sales.
License Property
Synagis is an antibody that provides the immune system with an increased ability to prevent infection.
Field of Use
The use is for respiratory syncytial virus ('RSV'), the leading cause of lower respiratory tract infections and pneumonia in infants and children worldwide.

IPSCIO Record ID: 3900

License Grant
Pursuant to an exclusive license agreement, the Company was granted exclusive Licenses in perpetuity for technologies developed by Licensor for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies.

The Company and Licensor have agreed, in principle, to an amendment to the existing Licensing Agreement to include additional virus types among the virus types the Company is permitted to manufacture, use, and offer for sale, and, Licensor has permitted the Company to use its nanomaterials to develop treatments for Dengue viruses, Ebola/Marburg viruses, and viruses causing viral Conjunctivitis (a disease of the eye), until such time as the Company and Licensor can complete an amendment to the Licensing Agreement to include these additional virus types we are permitted to manufacture, use and offer for sale.

Field of Use
The rights granted apply to the healthcare industry relating to life-threatening viral infections.

IPSCIO Record ID: 202385

License Grant
The Licensee entered into an exclusive license with the Licensor covering the underlying rotavirus vaccine technology used to generate the specific antibodies for our product line extension (First DefenseÃ’ Tri-Shieldâ„¢) that is under development.
License Property
The Vaccine technology is used for the Rotavirus – a contagious virus that can cause gastroenteritis (inflammation of the stomach and intestines).
Field of Use
First DefenseÃ’ Tri-Shieldâ„¢ is a natural treatment for scours, which causes diarrhea and dehydration in dairy and beef calves.

IPSCIO Record ID: 7238

License Grant
The Australian Licensor Licensed zanamivir on an exclusive, worldwide basis to the Belgium Licensee, which markets the product as Relenzaâ„¢.
License Property
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses.

Neuraminidase inhibitors work against influenza by preventing viruses from being released from infected cells and subsequently infecting further cells. Neuraminidase inhibitors are usually prescribed to patients presenting with flu-like symptoms during epidemic periods to reduce symptoms or prevent spread of the virus.

Field of Use
The Licensor's zanamivir, was developed as the first-in-class NI to treat influenza.

IPSCIO Record ID: 237256

License Grant
With this agreement, the English Licensor and the Licensee wish to settle legal proceedings by way of variation to the Patent License Agreement.   The original agreement is non-exclusive.
License Property
The amendment clarifies the licensed property includes, for the avoidance of doubt, Synagis.  The patent 6,632,927, is for the present invention relates to humanised antibody molecules.

Synagis is a humanized monoclonal antibody (“MAb”) approved for marketing in 1998 by the U.S. Food and Drug Administration (the “FDA”) for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (“RSV”) in pediatric patients at high risk of acquiring RSV disease (pneumonia and bronchiolitis).

Field of Use
Synagis® is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease.

IPSCIO Record ID: 4361

License Grant
Licensor hereby grants to Licensee an exclusive worldwide license, with the right to grant sublicensed, in all fields under the Licensed patents, to make, have made, use, sell, offer for sale and import Licensed Products and to use Licensed Products.
License Property
Licensor is the owner by assignment of certain intellectual property relating to the treatment with opioid antagonists (such as naltrexone) and (met-enkephalin), alone or in combination with standard of care treatments, of a variety of diseases and conditions, including multiple sclerosis, cancer of the prostate, Lymphoproliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, is treated in human patients by the administration, chronic herpes virus infections, chronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic, A treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS, those suffering from AIDS-related complex (ARC).  In particular, the inventions relate to methods and formulations for treatment of these conditions, including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to the intellectual property.

The Intellectual Property relates to treatments with opioid antagonists such as naltrexone and et-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).

Licensed Patents:
U.S. Patent Number 6,586,443
U.S. Patent Number 6,384,044
U.S. Patent Number 6,288,074
U.S. Patent Number 5,356,900
U.S. Patent Number 5,013,739
U.S. Patent Number 4,888,346

Field of Use
The Licensee's most advanced clinical programs involve immunotherapy using Met-enkephalin (“MENK”) and low dose naltrexone (“LDN”). Both immunotherapies work by triggering opioid receptors on immune cells leading to an activation and expansion of various cells of the immune system.

In clinical trials, MENK has been shown to reduce early AIDS and AIDS Related Complex, a condition also known as pre-AIDS which include symptoms such as fever, diarrhea, weight loss, swollen lymph nodes and herpes.

IPSCIO Record ID: 239029

License Grant
The RSV License Agreement amendment, between the University and Licensee, addresses the territory, Massachusetts and Maine, Net Sales, and royalties.
License Property
The property is for monoclonal antibody(ies) including, but not limited to, Synagis, which is an antibody that provides the immune system with an increased ability to prevent infection.
Field of Use
The use is for respiratory syncytial virus (RSV), the leading cause of lower respiratory tract infections and pneumonia in infants and children worldwide.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.